Combined Pdk And Mapk/erk Pathway Inhibition In Neoplasia


The current inventors have found a new method for treatment of malignant neoplasia. In particular the invention relates to the field of treating neoplasia in subject in need thereof and that involve (activated) MAPK/ERK pathway proteins, like BRAF melanomas and the like. Compositions for use in such treatment are provided which make use of pyruvate dehydrogenase kinase (PDK) inhibitors.

Download PDF
Document Preview
Document History
  • Publication: Jul 25, 2013
  • Application: Jan 16, 2013
    WO NL 2013050021 W
  • Priority: Jan 16, 2012
    US US 201261586978 P

Download Citation

Sign in to the Lens